MTOR and breast carcinoma: The pooled HRs for DFS, OS, and RFS were 0.71 (95% CI: 0.40–1.23), 0.84 (95% CI: 0.27–2.63), and 0.48 (95% CI: 0.20–1.18), respectively, which indicated no statistically significant relationship between p-mTOR expression and DFS, OS, and RFS in breast carcinoma patients.